tislelizumab + LBL-007

**tislelizumab + LBL-007** is an investigational combination therapy comprising two monoclonal antibodies: tislelizumab, an anti-PD-1 antibody developed by BeiGene, and LBL-007, a novel anti-LAG-3 antibody developed by Leads Biolabs. Both are immune checkpoint inhibitors: tislelizumab blocks programmed cell death protein 1 (PD-1), while LBL-007 targets lymphocyte activation gene-3 (LAG-3, CD223). The combination is designed to synergistically enhance anti-tumor immune responses by dual checkpoint inhibition. This combination is being studied in multiple indications, including advanced and metastatic solid tumors, nasopharyngeal carcinoma (NPC), and esophageal squamous cell carcinoma, in clinical trials up to Phase II. Typical regimens involve intravenous administration, and in some studies, the combination is tested alongside chemotherapy.

Brand names

Tevimbra

Other names

anti-PD-1 + anti-LAG-3 combination